1956
). The virus has caused clinical EKC when inoculated into the eyes of susceptible human volunteers, but has failed to produce clinical illness in the presence of type 8 serum antibody levels of 1:20 or greater (Mitsui, Hanabusa, Minoda, and Ogata, 1957) . Vaccines of adenovirus type 3 give rise to specific neutralizing antibodies in man and protect against subsequent challenge with the homologous type (Heubner, Bell, Rowe, Ward, Suskind, Hartley, and Paffenbarger, 1955) . The present study was undertaken to determine whether vaccination with adenovirus type 8 would induce specific antibodies and protect against subsequent challenge infection with either tissue-culture grown homologous virus, or infective material from typical cases of EKC.
Materials and Methods Virus Strains.-Two strains of adenovirus type 8 were employed: " Ishi " isolated from a typical case of EKC in Japan, and "Trim", the prototype strain, isolated in 1954 in California. Viruses were grown in HeLa cell cultures in a maintenance medium consisting of mixture 199 with 10 per cent. chick serum, penicillin, and streptomycin. The same tissue culture system was also employed for the isolation of adenovirus type 8 from active cases of EKC.
In addition to virus strains cultivated in vitro, conjunctival scrapings from active cases of EKC of less than 5 days' duration served as a source of infective virus for challenge. Part of such EKC scrapings served as inoculum for vaccinated or (Jawetz and others, 1956 Thus a total of 42 volunteers were vaccinated, and 37 of them showed a significant antibody response (Tables I and II) . (Table III, opposite) . This resistance was type-specific.
Two non-vaccinated volunteers who were inoculated with patient material (Nos. 43 and 44) had antibody titres of 10 or less before inoculation. Both developed an acute follicular conjunctivitis after 7 and 9 days' incubation respectively, and in one of them a subepithelial punctate keratitis appeared. There was a definite rise in the specific neutralizing antibodies to adenovirus type 8 during the illness in both volunteers.
Earlier results of inoculating non-vaccinated volunteers with TC-virus have been reported (Mitsui and others, 1957) , and are listed here for the sake of comparison. Five volunteers were inoculated with TC-virus on to the conjunctiva. Four of the five had pre-inoculation antibody titres of 10 or less. In all four, clinical EKC followed inoculation (Nos. [45] [46] [47] [48] , and in -Virus isolation was attempted in eighteen patients with early EKC, and adenovirus type 8 was recovered from twelve of them. Scrapings from these EKC donors had served as challenge inoculum for 23 volunteers. No other viruses were recovered in HeLa cell cultures from these donors. Satisfactory paired sera available in thirteen of these EKC donors all showed a significant rise in specific neutralizing antibodies to adenovirus type 8.
Discussion
The vaccine of adenovirus type 3 used by Huebner and others (1955) had a high infective titre of 300,000 TCD50/ml. In type 8 virus the infective titre is relatively low, rarely exceeding 300 TCD50/ml. Nevertheless, the virus content of our vaccine was sufficient to produce antibodies which protected against infection by the homologous virus. Another type 8 vaccine with an infective titre of 10 TCD50/ml. or less was not satisfactory.
It is evident that three vaccinations one week apart cause a definite antibody response; the post-vaccination antibody titre reaches 40 to 160. This titre is the same as that of convalescent serum of EKC patients. Two vaccinations at intervals of a week may also be adequate, but one vaccination is definitely insufficient. It may be assumed that specific neutralizing 36 antibody in a titre of 10 or less does not prevent the illness. Antibody levels of 20 or more prevent the illness in most instances.
Whereas the inoculation of humans with type 8 TC-virus has regularly caused clinical EKC in antibody-free volunteers, proper vaccination with type 8 virus regularly protected the volunteers. About 70-80 per cent. of the inoculations of volunteers with EKC patient material in Japan have shown a definite "take" (Aoki, 1941; Mitsui, 1948; Tanaka, 1957 Other types of adenoviruses have been isolated from similar conditions. Tanaka (1958) obtained an adenovirus type 7 and Ormsby, Fowle, and Doane (1957) obtained types 7 and 3 from donors with clinically similar illnesses. However, the inoculation studies of Tanaka and Watanabe (1958) and Sugiura (personal communication) clearly show that the clinical picture of illness resulting from adenovirus type 7 instilled into the eye differs markedly from typical EKC: the incubation period is short, and keratitis, if present at all, is not typical of EKC. The eye lesions of adenovirus type 3 infection were studied by our group in detail during recent outbreaks. They differ markedly from typical EKC, as detailed in a separate communication (Mitsui, Hanna, Hanabusa, Minoda, Ogata, Kurihara, Okamura, and Miura, 1959) .
Summary and Conclusions (1) The inoculation of adenovirus type 8, either grown in tissue culture or contained in fresh scrapings from typical cases of epidemic' kerato-congroup.bmj.com on October 29, 2017 -Published by http://bjo.bmj.com/ Downloaded from junctivitis (EKC), induced typical EKC in the human eye. The subcutaneous inoculation of viable adenovirus type 8 had no clinically observable effect whatever.
(2) Human volunteers vaccinated with two or three injections of viable adenovirus type 8 developed specific neutralizing antibodies to this virus and at the same time became resistant to ocular challenge inoculation with the agent. This immunity was strictly type-specific.
(3) The experiments reported here strongly support the impression that adenovirus type 8 is the principal aetiological agent causing epidemic keratoconjunctivitis in Japan.
